Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$135.25
+3.1%
$129.58
$108.46
$157.29
$162.83B0.326.43 million shs10.08 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,115.68
-0.5%
$1,154.75
$623.78
$1,249.45
$1.06T0.512.38 million shs4.08 million shs
Medtronic PLC stock logo
MDT
Medtronic
$86.16
-0.6%
$81.27
$73.31
$106.33
$110.95B0.557.41 million shs6.36 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.35
+1.3%
$25.02
$23.58
$28.75
$142.66B0.3438.54 million shs61.35 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.72%+0.48%-0.09%-1.75%+15.88%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.35%-6.31%-7.12%+13.48%+47.39%
Medtronic PLC stock logo
MDT
Medtronic
+1.20%+2.82%+4.33%+11.44%-2.96%
Pfizer Inc. stock logo
PFE
Pfizer
-0.20%+1.52%+3.12%-5.19%+6.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$135.25
+3.1%
$129.58
$108.46
$157.29
$162.83B0.326.43 million shs10.08 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,115.68
-0.5%
$1,154.75
$623.78
$1,249.45
$1.06T0.512.38 million shs4.08 million shs
Medtronic PLC stock logo
MDT
Medtronic
$86.16
-0.6%
$81.27
$73.31
$106.33
$110.95B0.557.41 million shs6.36 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.35
+1.3%
$25.02
$23.58
$28.75
$142.66B0.3438.54 million shs61.35 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.72%+0.48%-0.09%-1.75%+15.88%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.35%-6.31%-7.12%+13.48%+47.39%
Medtronic PLC stock logo
MDT
Medtronic
+1.20%+2.82%+4.33%+11.44%-2.96%
Pfizer Inc. stock logo
PFE
Pfizer
-0.20%+1.52%+3.12%-5.19%+6.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.86
Moderate Buy$157.9316.77% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,283.6415.05% Upside
Medtronic PLC stock logo
MDT
Medtronic
2.67
Moderate Buy$98.8314.71% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.5012.41% Upside

Current Analyst Ratings Breakdown

Latest GILD, MDT, PFE, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Reiterated RatingOverweight
7/29/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Lower Price TargetEqual Weight$155.00 ➝ $145.00
7/28/2026
Medtronic PLC stock logo
MDT
Medtronic
UpgradeNeutralBuy$85.00 ➝ $100.00
7/27/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Lower Price TargetOverweight$166.00 ➝ $165.00
7/21/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
DowngradeOutperformMarket Perform$146.00 ➝ $127.00
7/15/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,500.00 ➝ $1,600.00
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,250.00 ➝ $1,425.00
7/13/2026
Medtronic PLC stock logo
MDT
Medtronic
Reiterated RatingBuy$91.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,235.00 ➝ $1,273.00
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B5.70$10.79 per share12.53$18.23 per share7.42
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B16.12$25.01 per share44.61$28.07 per share39.75
Medtronic PLC stock logo
MDT
Medtronic
$36.36B3.03$7.80 per share11.04$39.00 per share2.21
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.31$4.46 per share5.69$15.26 per share1.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B$7.3418.4313.90N/A30.99%48.19%18.28%8/4/2026 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1539.6324.801.3934.98%105.77%23.76%8/5/2026 (Estimated)
Medtronic PLC stock logo
MDT
Medtronic
$4.80B$3.7323.1013.502.3213.20%14.51%7.76%8/18/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.358.90N/A11.83%19.44%8.41%8/4/2026 (Estimated)

Latest GILD, MDT, PFE, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/1/2026Q1 2027
Medtronic PLC stock logo
MDT
Medtronic
$1.39N/AN/AN/A$9.55 billionN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.06N/AN/AN/A$20.69 billionN/A
8/4/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.26-$6.75+$0.51-$8.45$7.40 billionN/A
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.68$0.77+$0.09-$0.04$14.40 billion$15.03 billion
6/3/2026Q4 2026
Medtronic PLC stock logo
MDT
Medtronic
$1.54$1.55+$0.01$0.96$9.62 billion$9.81 billion
5/7/2026Q1 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.43%+3.04%44.69%10 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.62%+15.18%24.58%11 Years
Medtronic PLC stock logo
MDT
Medtronic
$2.883.34%+4.13%77.21%49 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.78%-13.20%131.30%16 Years

Latest GILD, MDT, PFE, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
6/3/2026
Medtronic PLC stock logo
MDT
Medtronic
quarterly$0.723.56%6/26/20266/26/20267/17/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.89
1.97
1.77
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Medtronic PLC stock logo
MDT
Medtronic
0.52
2.13
1.62
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Medtronic PLC stock logo
MDT
Medtronic
82.06%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Medtronic PLC stock logo
MDT
Medtronic
0.26%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Medtronic PLC stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Inc. Q2 2026 Earnings Call Summary
Pfizer (NYSE:PFE) Shares Up 1.3% Following Earnings Beat
The $85 Billion Consolation Prize For JNJ Shareholders
Sector Update: Healthcare Stocks Softer Late Afternoon
Pfizer Earnings Reveal New Engine Beyond Covid
Pfizer raises revenue outlook after quarterly earnings top estimates
Pfizer's Recovery Story Is Starting to Look More Durable
Pfizer (NYSE:PFE) Issues Quarterly Earnings Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$135.25 +4.10 (+3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$134.29 -0.96 (-0.71%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,115.68 -5.68 (-0.51%)
Closing price 03:59 PM Eastern
Extended Trading
$1,129.00 +13.32 (+1.19%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic stock logo

Medtronic NYSE:MDT

$86.16 -0.52 (-0.60%)
Closing price 03:59 PM Eastern
Extended Trading
$86.36 +0.20 (+0.23%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Pfizer stock logo

Pfizer NYSE:PFE

$25.35 +0.32 (+1.29%)
Closing price 03:59 PM Eastern
Extended Trading
$25.32 -0.03 (-0.11%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.